Voloridge Investment Management LLC Purchases 1,059,751 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Voloridge Investment Management LLC grew its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 226.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,526,994 shares of the company's stock after purchasing an additional 1,059,751 shares during the period. Voloridge Investment Management LLC owned approximately 1.50% of Intellia Therapeutics worth $17,805,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Vestal Point Capital LP purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth $6,122,000. Squarepoint Ops LLC raised its stake in shares of Intellia Therapeutics by 58.8% during the 4th quarter. Squarepoint Ops LLC now owns 101,417 shares of the company's stock worth $1,183,000 after buying an additional 37,533 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after buying an additional 970,700 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock worth $21,498,000 after buying an additional 863,363 shares during the last quarter. Finally, Teza Capital Management LLC raised its stake in shares of Intellia Therapeutics by 74.3% during the 4th quarter. Teza Capital Management LLC now owns 26,065 shares of the company's stock worth $304,000 after buying an additional 11,107 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NTLA shares. Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target for the company in a research note on Monday, April 21st. Wells Fargo & Company cut their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim cut their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. The Goldman Sachs Group reissued a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $36.90.

Intellia Therapeutics Stock Up 3.4%

Shares of NTLA traded up $0.32 during trading hours on Wednesday, reaching $9.65. The company's stock had a trading volume of 813,113 shares, compared to its average volume of 2,566,442. The firm has a market cap of $999.27 million, a price-to-earnings ratio of -1.78 and a beta of 2.33. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The company has a 50 day moving average of $7.99 and a two-hundred day moving average of $10.45.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics's revenue for the quarter was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.12) EPS. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.